- Liz Highleyman | 02 March 2016
Participants taking tenofovir/emtricitabine
(Truvada) for pre-exposure
prophylaxis (PrEP) in two major studies experienced modest declines in kidney
function that were associated with higher tenofovir drug levels and older age,
according to studies presented in ...
- Keith Alcorn | 01 March 2016
Entry into HIV care can be increased by around 40% if people
receive a point-of-care CD4 test and counselling sessions to overcome personal
barriers to seeking HIV care, a large randomised study ...
- Carole Leach-Lemens | 01 March 2016
Engaging lay
counsellors to provide a combination package of evidence-based interventions in
Nyanza, Kenya and addressing partner disclosure, as well as pre-treatment education
about the benefits of antiretroviral therapy (ART) for maternal and ...
- Liz Highleyman | 29 February 2016
GS-9620, an
investigational toll-like receptor or TLR7 agonist, led to immune activation in
a study of macaque monkeys infected with an HIV-like virus, and two of the
animals treated with multiple doses have ...
- Keith Alcorn | 29 February 2016
The quadrivalent HPV vaccine Gardasil does not protect older adults
with HIV against persistent anal infection with human papillomavirus (HPV) or the
development of HSIL, but the ACTG A5298 study showed some ...
- Gus Cairns | 28 February 2016
Results from the MTN-017 study of 1% tenofovir gel as a
rectal microbicide were presented to the Conference on Retroviruses and Opportunistic Infections (CROI 2016) on Wednesday. The
study compares the safety ...
- Gus Cairns | 28 February 2016
A study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) comparing life
expectancies of HIV-positive and HIV-negative people within the Kaiser
Permanente health insurance system has found that although ...
- Roger Pebody | 27 February 2016
In four years, Malawi’s treatment cascade for pregnant women
has been transformed so that the proportion of women with HIV who are
diagnosed has gone from 49 to 80%, and the proportion ...
- Gus Cairns | 26 February 2016
An analysis of
condom use in the placebo-controlled phase of the French IPERGAY trial of
intermittent pre-exposure prophylaxis (PrEP), presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016), found that ...
- Theo Smart | 26 February 2016
A South
African trial has found that a strategy allowing primary care nurses to quickly
provide empirical tuberculosis (TB) treatment for newly diagnosed people with
advanced HIV disease at very high risk of, ...
- Liz Highleyman | 26 February 2016
An interferon- and ribavirin-free regimen of
sofosbuvir/ledipasvir (Harvoni) taken
for just 6 weeks was enough to cure hepatitis C in HIV-positive people with recent
hepatitis C virus (HCV) infection if their HCV viral ...
- Keith Alcorn | 25 February 2016
Offering TB screening as part of a home-based HIV testing
intervention has the potential to identify numerous TB cases that
would otherwise have gone undiagnosed, a
report from a large community-based study in ...
- Gus Cairns | 25 February 2016
A case report of a man in Toronto who became infected with a
multi-drug-resistant strain of HIV despite apparently very consistent adherence
to PrEP was presented at the Conference on Retroviruses and ...
- Keith Alcorn | 25 February 2016
People who started antiretroviral therapy at a CD4 cell
count above 500 had a significantly lower risk of developing a cancer with an
infectious cause when compared to people who started treatment ...
- Theo Smart | 25 February 2016
In the future, HIV-associated neurocognitive disorder
(HAND) may become less common because of the earlier use of antiretroviral
therapy (ART), but neurological disease – caused by a number of different
factors – will ...
- Roger Pebody | 25 February 2016
Making point-of-care CD4 count diagnostics available, revising
adherence counselling requirements and giving extra training to healthcare
workers can almost quadruple the number of patients who begin antiretroviral therapy on
the day that they ...
- Carole Leach-Lemens | 25 February 2016
Dolutegravir (DTG) plus optimised
background regimen (OBR) is safe, well tolerated and provides virologic
efficacy in HIV-infected children from six to 12 years of age at 48 weeks, Andrew
Wiznia presenting on behalf ...
- Gus Cairns | 25 February 2016
The Conference on Retroviruses and Opportunistic Infections (CROI 2016) heard results yesterday from the
first phase 2 (safety, acceptability and dose-finding) study of a long-lasting,
injectable formulation of the integrase-inhibitor drug cabotegravir ...
- Liz Highleyman | 25 February 2016
A proof-of-concept study
showed that the new tenofovir alafenamide (TAF) plus emtricitabine (FTC, Emtriva) protected macaques from
infection with an HIV-like virus, with a degree of protection similar to that
previously seen with ...
- Liz Highleyman | 25 February 2016
A fixed-dose coformulation of
tenofovir alafenamide (TAF) and emtricitabine (FTC, Emtriva), combined with a variety of third antiretroviral agents,
maintained undetectable viral load in people who switched from similar regimens
containing the older ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...